Table 2 Body weight, hepatic triglyceride content and metabolic factors change from baseline to after 26 weeks of treatment in the MAGNA VICTORIA study.

From: Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort

Characteristic

Mean ± SD change from baseline to 26 weeks

Mean [95%CI] changes from baseline (liraglutide vs placebo)

P value

Liraglutide (n = 22)

Placebo (n = 25)

Clinical parameters

Body weight (kg)

−4.3 ± 3.8

0.1 ± 2.5

−4.5 [−6.4, −2.6]

<0.001

BMI (kg/m2)

−1.5 ± 1.3

0.1 ± 0.8

−1.5 [−2.2, −0.9]

<0.001

Hepatic triglyceride content (%)

−6.3 ± 7.1

−4.0 ± 4.6

−2.1 (−5.3, 1.0)

0.174

Metabolic factors

CETP (µg/mL)

−0.05 ± 0.20

−0.04 ± 0.18

0.00 [−0.10, 0.11]

0.977

Total cholesterol (mmol/L)

−0.72 ± 0.89

−0.46 ± 0.56

−0.22 [−0.59, 0.15]

0.231

HDL-cholesterol (mmol/L)

−0.02 ± 0.14

0.05 ± 0.25

−0.08 [−0.20, 0.05]

0.222

LDL-cholesterol (mmol/L)

−0.44 ± 0.51

−0.24 ± 0.52

−0.17 [−0.44, 0.10]

0.218

Triglycerides (mmol/L)

−0.50 ± 1.12

−0.60 ± 0.98

0.23 [−0.11, 0.56]

0.177

Glucose (mmol/L)

−1.7 ± 2.2

−0.6 ± 2.2

−0.5 [−1.7, 0.7]

0.434

HbA1c (%)

−1.1 ± 1.0

−0.7 ± 0.9

−0.3 [−0.8, 0.2]

0.265

HbA1c (mmol/mol)

−11.6 ± 11.1

−7.7 ± 9.4

−2.9 [−8.1, 2.3]

0.265

AST (IU/L)

−6 ± 11

−12 ± 22

2 [−3, 6]

0.459

ALT (IU/L)

16 ± 12

14 ± 10

1 [−5, 7]

0.778

  1. Results are presented as mean ± SD. n = 47. Missing data: n = 2 for hepatic triglyceride content in the placebo group, n = 1 for hepatic triglyceride content, n = 1 for LDL-cholesterol and n = 1 for glucose in the liraglutide group. ALT: alanine transaminase, AST: aspartate transaminase, CETP: cholesteryl ester transfer protein, HbA1c: glycated haemoglobin.
Back to article page